Technology Roadmapping, Part 3: Enabling Technologies and Capabilities by magma | Apr 27, 2017 | Articles, Technology Roadmapping News | 0 comments Although great strides have been made over the past 20 years to increase the productivity and robustness of manufacturing processes for biopharmaceuticals, the cost and complexity of their development and manufacturing remain high, especially in comparison with those of small-molecule pharmaceuticals. Process improvements are required to increase patient access while maintaining the viability of an R&D-driven biopharmaceutical industry. Facility productivity, cost of goods (CoG), and capital investment all have significant margins for improvement. Read the full article in April’s issue of BioProcess International Submit a Comment Cancel reply Your e-mail address will not be published. Required fields are marked *Comment Name * Email * Website Save my name, e-mail, and website in this browser for the next time I comment. This site uses Akismet to reduce spam. Learn how your comment data is processed.